DISRUPTION OF ASXL1 IN T CELLS TO ENHANCE IMMUNOTHERAPY
Application
US20260091115A1
Kind: A1
Apr 02, 2026
Assignee
St. Jude Children's Research Hospital, Inc.
Inventors
Benjamin YOUNGBLOOD, Caitlin ZEBLEY, Tae Gun KANG, Kirsten Grønbæk
Abstract
The application relates to modified immune effector cells with enhanced immune cell function, as well as related pharmaceutical compositions. The application further relates to methods for generating the modified immune effector cell and methods for using the modified immune effector cell for treatment of diseases (e.g., adoptive cell therapy).
CPC Classifications
A61K 40/4217
A61K 40/11
A61K 40/31
A61K 40/4205
C07K 14/7051
C07K 16/2866
C07K 16/32
C12N 9/226
C12N 15/11
C12N 15/907
C07K 2317/622
C12N 2310/20
Filing Date
2023-09-15
Application No.
19112045